Copertina

Ibuprofen inhibits human sweet taste and glucose detection implicating an additional mechanism of metabolic disease risk reduction

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Emily C. Hanselman, Caroline P. Harmon, Daiyong Deng, Sarah M. Sywanycz, Lauren Caronia, Peihua Jiang, Paul A. S. Breslin
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	British Journal of Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Topical application of a P2X2/P2X3 purine receptor inhibitor suppresses the bitter taste of medicines and other taste qualities
di: Linda J. Flammer, et al.
Pubblicazione: (2024)

The sodium–glucose co‐transporter 2 inhibitor, empagliflozin, attenuates pulmonary vascular remodelling by inhibiting the phosphorylation of PDGF receptor‐β
di: Ting‐ting Lyu, et al.
Pubblicazione: (2025)

Paradoxical mitochondrial effects of nitric oxide synthase inhibition following oxygen–glucose deprivation–reoxygenation (OGD/R) in endothelial cells and neurons
di: Venkata N. Sure, et al.
Pubblicazione: (2025)

Klebsiella pneumoniae contributes to altered cytotoxicity of thiopurines in vitro: Possible implications of biotransformation and bacterial metabolism
di: Martina Franzin, et al.
Pubblicazione: (2025)

Altered desensitization and internalization patterns of rodent versus human glucose‐dependent insulinotropic polypeptide (GIP) receptors. An important drug discovery challenge
di: Lærke Smidt Gasbjerg, et al.
Pubblicazione: (2024)

Adjunctive therapy with an oral H2S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction
di: Jake E. Doiron, et al.
Pubblicazione: (2024)

Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF‐ĸB signalling pathway
di: Camila Leiva‐Castro, et al.
Pubblicazione: (2025)

PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells
di: Dennis Reininger, et al.
Pubblicazione: (2024)

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach
di: Judith Berres, et al.
Pubblicazione: (2026)

Glycolytic metabolism of CD8 + T‐cells affects susceptibility to human leukocyte antigen‐mediated abacavir‐induced hypersensitivity
di: Takeshi Susukida, et al.
Pubblicazione: (2026)

Characterisation of cotadutide's dual GLP‐1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology model
di: Rolien Bosch, et al.
Pubblicazione: (2024)

FM‐dye inhibition of Piezo2 relieves mechanically evoked pain in mouse models of acute inflammatory and osteoarthritic knee pain
di: Natalie S. Adamczyk, et al.
Pubblicazione: (2026)

Sodium‐glucose cotransporter‐2 inhibitors and the risk of lung cancer among patients with type 2 diabetes
di: Samantha B. Shapiro, et al.
Pubblicazione: (2024)

A scoping review of disease‐modifying antirheumatic drug nonadherence in rheumatoid arthritis: Measurement, prevalence and implications for clinical practice
di: Lauren Fraser, et al.
Pubblicazione: (2025)

Therapeutic drug monitoring, liquid biopsies or pharmacogenomics for prediction of human drug metabolism and response
di: Magnus Ingelman‐Sundberg, et al.
Pubblicazione: (2024)

Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis
di: Jie Ren, et al.
Pubblicazione: (2025)

Investigation of absorption, metabolism, and excretion of [ 14 C]pruxelutamide (GT0918), an androgen receptor antagonist in humans
di: Yuan‐dong Zheng, et al.
Pubblicazione: (2025)

Bruton's tyrosine kinase inhibition suppresses pathological retinal angiogenesis
di: Siyue Chen, et al.
Pubblicazione: (2024)

Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells
di: Marco Hoffmann, et al.
Pubblicazione: (2026)

ESG‐1‐60 and ESG‐1‐61: Novel dopamine D3 receptor‐preferring partial agonists/antagonists that inhibit cocaine taking and seeking in rodents
di: Omar Soler‐Cedeño, et al.
Pubblicazione: (2025)

Targeted peptide‐modified M2 exosomes drug delivery system for the targeted regulation of the lung injury microenvironment with isorhynchophylline (IRN): based on the inflammatory–metabolic–epigenetic synergy mechanism
di: Jin‐Ru Zou, et al.
Pubblicazione: (2026)

Targeting FDX1 by trilobatin to inhibit cuproptosis in doxorubicin‐induced cardiotoxicity
di: Jiajia Wei, et al.
Pubblicazione: (2025)

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users
di: Haoxin Le, et al.
Pubblicazione: (2026)

Carvedilol inhibits neuronal hyperexcitability caused by epilepsy‐associated KCNT1 mutations
di: Chang Di, et al.
Pubblicazione: (2024)

Bortezomib promotes neutrophil‐mediated bacterial clearance in sepsis by inhibiting plasmablast activation
di: Wang Jianyao, et al.
Pubblicazione: (2026)

Bispecific nanobody® as a new pharmacological drug for the selective inhibition of Trypsin‐3
di: Melissa David, et al.
Pubblicazione: (2025)

Covalent fluorescent probes for 2‐arachidonoylglycerol metabolic pathways
di: Nick D. F. Puijmbroeck, et al.
Pubblicazione: (2026)

Pharmacological inhibition of STING reduces neuroinflammation‐mediated damage post‐traumatic brain injury
di: Amelia L. Fryer, et al.
Pubblicazione: (2024)

Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China
di: Feng Zhang, et al.
Pubblicazione: (2024)

SGLT2 inhibitors and their influence on iron metabolism in the context of inflammation
di: Helene G. Meyer, et al.
Pubblicazione: (2025)

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
di: Andrea Baragetti, et al.
Pubblicazione: (2026)

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?
di: Luca Botticelli, et al.
Pubblicazione: (2025)

Insulin‐degrading enzyme inhibition increases the unfolded protein response and favours lipid accumulation in the liver
di: Marine Andres, et al.
Pubblicazione: (2024)

Activation of the pentose phosphate pathway flux by hydrogen peroxide is not regulated by NADPH‐mediated feedback inhibition
di: Camila Aburto, et al.
Pubblicazione: (2025)

Genetic deficiency or pharmacological inhibition of cGAS–STING signalling suppresses kidney inflammation and fibrosis
di: Baihai Jiao, et al.
Pubblicazione: (2025)

Matrix metalloproteinase inhibition protects against junctophilin‐2 proteolysis during doxorubicin‐induced cardiotoxicity
di: Wesam Bassiouni, et al.
Pubblicazione: (2025)

Ginsenosides retard atherogenesis via remodelling host–microbiome metabolic homeostasis
di: Yun Wang, et al.
Pubblicazione: (2024)

Correction to “AQX‐1125, small molecule SHIP1 activator inhibits bleomycin‐induced pulmonary fibrosis”
Pubblicazione: (2024)

SEW2871 attenuates myocyte necroptosis in heart failure through inhibition of oxidative stress and inflammatory cytokines
di: Hong‐Xia Guo, et al.
Pubblicazione: (2025)

Histone deacetylase inhibition mitigates cognitive deficits and astrocyte dysfunction induced by amyloid‐β (Aβ) oligomers
di: Luan Pereira Diniz, et al.
Pubblicazione: (2024)